Compare RAVE & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAVE | TELA |
|---|---|---|
| Founded | 1958 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 50.8M |
| IPO Year | N/A | 2019 |
| Metric | RAVE | TELA |
|---|---|---|
| Price | $3.19 | $0.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.31 |
| AVG Volume (30 Days) | 38.2K | ★ 81.2K |
| Earning Date | 02-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.08 | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | $12,202,000.00 | ★ $77,055,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | N/A | $15.20 |
| P/E Ratio | $16.24 | ★ N/A |
| Revenue Growth | 0.73 | ★ 12.24 |
| 52 Week Low | $2.01 | $0.86 |
| 52 Week High | $3.75 | $2.96 |
| Indicator | RAVE | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 36.58 |
| Support Level | $3.15 | $1.08 |
| Resistance Level | $3.40 | $1.16 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 21.17 | 21.28 |
Rave Restaurant Group Inc operates and franchises pizza buffet, delivery/carry-out, express restaurants, and ghost kitchens. It operates restaurants under the brand name, Pizza Inn, and Pie Five Pizza Company. It has three operating segments. The Pizza Inn Franchising and Pie Five Franchising segments establish franchisees, licensees, and territorial rights. The corporate administration and other segments. The Pizza Inn Franchising segment accounts for the majority of the company's revenue. Geographically, it generates the majority of the revenue from the United States.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.